Humana Inc. $HUM Shares Sold by AMG National Trust Bank

Key Points

• AMG National Trust Bank trimmed its stake in Humana by 42.4% in Q4, selling 7,189 shares and leaving 9,764 shares valued at about $2.50 million, amid active institutional trading (92.38% ownership).
• Analyst sentiment is mixed: the consensus rating is Hold with an average target of $222.09, alongside notable price-target cuts (TD Cowen to $173, Cantor Fitzgerald to $201) and some raises (Wells Fargo to $227, Evercore to $195).
• Humana beat Q1 estimates (EPS -$3.96 vs. -$4.01) and revenue, set FY2026 guidance at 9.00 EPS (analysts expect 9.05), declared a $0.885 quarterly dividend (1.5% yield), and announced a strategic pharmacy tie-up with Mark Cuban’s Cost Plus Drugs plus a modestly favorable Medicare Advantage 2027 payment outlook as potential catalysts.

AMG National Trust Bank trimmed its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 42.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,764 shares of the insurance provider's stock after selling 7,189 shares during the quarter. AMG National Trust Bank's holdings in Humana were worth $2,501,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. CoreCap Advisors LLC grew its stake in Humana by 54.4% during the 4th quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider's stock worth $27,000 after purchasing an additional 37 shares in the last quarter. Rosenberg Matthew Hamilton lifted its holdings in shares of Humana by 136.0% in the 4th quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider's stock valued at $30,000 after purchasing an additional 68 shares during the last quarter. Mather Group LLC. purchased a new stake in shares of Humana in the 3rd quarter valued at about $34,000. Larson Financial Group LLC increased its position in Humana by 114.1% in the 3rd quarter. Larson Financial Group LLC now owns 152 shares of the insurance provider's stock valued at $40,000 after acquiring an additional 81 shares during the period. Finally, Fulcrum Asset Management LLP acquired a new position in Humana in the 3rd quarter valued at about $42,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

HUM has been the topic of several recent research reports. TD Cowen dropped their price target on Humana from $260.00 to $173.00 and set a "hold" rating on the stock in a research report on Friday, February 13th. Wells Fargo & Company boosted their price target on Humana from $206.00 to $227.00 and gave the company an "equal weight" rating in a research report on Tuesday, April 7th. Weiss Ratings restated a "sell (d+)" rating on shares of Humana in a research report on Tuesday, April 21st. Cantor Fitzgerald dropped their price target on Humana from $290.00 to $201.00 and set a "neutral" rating on the stock in a research report on Thursday, February 12th. Finally, Evercore boosted their price target on Humana from $180.00 to $195.00 in a research report on Wednesday, April 8th. Seven research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $222.09.

Humana Stock Performance

NYSE HUM opened at $230.32 on Wednesday. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 0.70. The business's 50 day moving average is $186.35 and its two-hundred day moving average is $227.34. Humana Inc. has a 12-month low of $163.11 and a 12-month high of $315.35. The stock has a market capitalization of $27.65 billion, a price-to-earnings ratio of 23.45, a PEG ratio of 2.40 and a beta of 0.44.

Humana (NYSE:HUM - Get Free Report) last released its earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.01) by $0.05. Humana had a return on equity of 11.43% and a net margin of 0.92%.The company had revenue of $32.64 billion for the quarter, compared to analysts' expectations of $32.08 billion. During the same quarter in the previous year, the firm posted ($2.16) EPS. The firm's quarterly revenue was up 11.3% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. Research analysts expect that Humana Inc. will post 9.05 EPS for the current year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be issued a $0.885 dividend. The ex-dividend date is Friday, June 26th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.5%. Humana's dividend payout ratio is currently 36.05%.

Key Humana News

Here are the key news stories impacting Humana this week:

• Positive Sentiment: New strategic pharmacy tie-up with Mark Cuban’s Cost Plus Drugs expands CenterWell’s distribution and employer-focused drug offerings — a potential margin and growth tailwind if it scales. Humana partners with Mark Cuban's Cost Plus Drugs on technology, distribution
• Positive Sentiment: Medicare Advantage payment rules for 2027 look modestly favorable (CMS projected ~2.48% increase), improving revenue visibility for MA-focused insurers like Humana and supporting sentiment into earnings. Humana rises 3.9% ahead of earnings as Medicare Advantage rate outlook supports sentiment
• Neutral Sentiment: Q1 2026 earnings release is scheduled for April 29 — a near-term catalyst that’s driving positioning; investors will focus on medical-cost trends, membership metrics and FY guidance. Earnings to watch: Humana (HUM) reports Q1 results tomorrow
• Neutral Sentiment: Humana is rallying alongside UnitedHealth as the managed‑care sector rebounds in April; part of the move reflects broader sector rotation rather than company‑specific news. UnitedHealth and Humana Soar in April: Which Healthcare Stock Is Winning and Why
• Negative Sentiment: Analyst and media caution: Humana’s share performance has been volatile this year due to uncertainty around how much the government will pay Medicare Advantage plans — downside risk remains if reimbursement pressure reappears or guidance disappoints. Humana Earnings Could Signal If More Medicare Advantage Members Is a Good Thing

Insider Buying and Selling at Humana

In other news, insider Sanjay K. Shetty purchased 810 shares of the stock in a transaction that occurred on Monday, February 23rd. The shares were acquired at an average price of $185.21 per share, for a total transaction of $150,020.10. Following the acquisition, the insider directly owned 11,657 shares in the company, valued at approximately $2,158,992.97. The trade was a 7.47% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.20% of the stock is currently owned by corporate insiders.

Humana Profile

Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.